NCT07178340View on ClinicalTrials.gov

Phase II Clinical Study for HER2-negative Hepatoid Adenocarcinoma of Stomach

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 20, 2025

Primary Completion Date

September 20, 2027

Study Completion Date

September 20, 2028

Conditions
Hepatoid Adenocarcinoma of Stomach
Interventions
DRUG

Perioperative treatment

perioperative treatment with albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules and sintilimab

Trial Locations (1)

Unknown

Peking University Cancer Hospital & Institute, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER